No phaseActive, not recruiting
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization (TARGET)
The Use of Thromboelastography With Platelet Mapping to Guide Thromboprophylaxis Following Lower Extremity Revascularization for Peripheral Artery Disease
- Sponsor
- Massachusetts General Hospital (Academic or other)
- Enrolment
- 144 enrolled
- Conditions
- Thrombosis; Arterial Occlusive Diseases; Thromboelastography (TEG); Peripheral Arterial Disease(PAD); Stent Thrombosis; Platelet Inhibition; PRU(Platelet Reactivity Unit)
- Interventions
- Aspirin; Clopidogrel; Ticagrelor; Platelet Reactivity Testing; Thromboelastography with Platelet Mapping
- Ages
- adults, older adults
- Registry
- NCT07597239
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to learn if a blood clotting test called thromboelastography with platelet mapping (TEG-PM) can guide blood-thinning medication decisions in adults more than 60 years and older with peripheral artery disease (PAD) who have undergone infrainguinal endovascular surgery. The main questions it aims to answer are: * Does TEG-PM-guided antiplatelet therapy lower the rate of thrombosis or clinically significant stenosis of the treated artery within 12 months compared with a historical standard-of-care cohort? * How does TEG-PM-guided therapy affect major amputation, amputation-free survival, mortality, and bleeding? Participants will: * Have blood samples taken before the procedure and at 1, 3, and 6 months afterward * Have antiplatelet medications (aspirin, clopidogrel, and/or ticagrelor) escalated or de-escalated based on TEG-PM results through 6 months * Have one additional blood test to check clopidogrel response if taking clopidogrel * Be followed for clinical outcomes through 12 months
Primary outcomes
- Target-Vessel Thrombosis or Clinically Significant Stenosis
History
Study completion
Last registry update
Registered
Primary completion
Started